 Our study demonstrated that activation of AMPK signaling pathway ameliorates diabetic nephropathy by modifying serum albumin, uric acid, total protein, and creatinine levels and attenuating kidney damage. In addition, we found that dorsomorphin, an AMPK inhibitor, reverses the beneficial effects of AMPK on diabetic nephropathy. These findings suggest that AMPK signaling pathway may represent a potential therapeutic target for diabetic nephropathy. This article was authored by Amin Hazenband, Hossain Amimikoi, Samani Jahanabadi, and others.